I don't have access to the full article. But what they are talking about in the parts of their study available to public all has been discussed here many times including the reference to potentials for other peptide drug conjugates using other anti cancer drugs(warheads) among others!!
A bit of exposure and recognition in China is definitely useful..
"Highlights
The novel TH19P01-camptothecin (CPT) conjugates were designed, efficiently synthesized, and evaluated for their anticancer potential.
The hybrid peptide LYJ-2 could quickly enter the SORT1 high-expressed cancer cells, the efficiency of which was significantly higher than that of free CPT.
LYJ-2 exhibited selective anti-proliferative and anti-migration effects against SORT1-positive cancer cells.
Through conjugating with TH19P01, both the water solubility and anticancer selectivity of CPT could be significantly improved.
The TH19P01-CPT based hybrid peptides hold potential for the further development of promising PDCs against SORT1 high-expressed cancer cells."
https://www.sciencedirect.com/science/article/abs/pii/S0968089624002839?via%3Dihub